3-Deazauridine, a synthetic analogue of uridine and a potential antitumor agent, was found to possess antiviral activity against a number of ribonucleic acid-contaming animal viruses in mammalian cell culture. Inhibition of virus-induced cytopathogenic effects by 3-deazauridine was observed in cells infected with rhinovirus types 1A and 13, coxsackievirus type A21, and PR-8 influenza virus, but not in cells infected with poliovirus type 2 or echovirus type 12 . The extracellular yield of progeny influenza virus was found to be significantly reduced in titer in 3-deazauridinetreated Madin-Darby canine kidney cell cultures at 12 to 24 hr after infection. Although the precise biochemical mechanism of action of this antimetabolite's antiviral activity is not known, the compound does not appear to exert a direct virucidal effect on the influenza virion itself.
The synthesis of 3-deazauridine (deaza-UR), a pyridine analogue of the naturally occurring pyrimidine nucleoside uridine ( Fig. 1) , was reported by Robins and Currie (4, 15 (7) . From our experience, a VR of > 1.0 is indicative of definite antiviral activity, whereas a VR of 0.5 to 0.9 is indicative of moderate or questionable antiviral activity, and a VR of <0.5 suggests no apparent antiviral activity (19) .
Effect of deaza-UR on the multiplication of influenza virus. Replicate MDCK cell monolayers, grown in 25-cm2 plastic cell culture flasks (Falcon Plastics, Division of BioQuest, Oxnard, Calif.), were rinsed once with warm phosphate-buffered saline (PBS) and were inoculated with 100 CCID50 of influenza virus in 0.5 ml of medium or, for uninfected controls, with 0.5 ml of medium alone. Deaza-UR was added in a volume of 0.5 ml of medium to each of the infected cultures to be treated, immediately after virus inoculation, to yield a final concentration of 10, 32, 100, 320, or 1,000 jug of deaza-UR per ml. Medium alone was added to the untreated, virus-infected control cultures, and medium containing deaza-UR was added to those uninfected cell cultures serving as drug cytotoxicity controls. The flasks were incubated at 37 C for a 1-hr period of adsorption, after which the culture fluids were decanted and the cells were again rinsed with warm PBS. Fresh growth medium (6.0 ml) containing deaza-UR at the appropriate concentration or, for controls, fresh growth medium alone was added to each cell culture flask, and the cultures were returned to the incubator at 37 C. At 4, 12, and 24 hr after virus inoculation, three drugtreated, virus-infected cultures from each drug dose level and three untreated, virus-infected control cultures were removed and assayed for extracellular virus. After low-speed centrifugation of the cell culture fluids to remove cells, samples of the supernatant fluids were removed, and serial 10-fold dilutions of the samples were prepared in fresh growth medium. Samples (1 ml) of each dilution were added to each of five plastic titration panel wells containing suitable MDCK cell monolayers, after which the panels were sealed and incubated at 37 C. The cell cultures were examined microscopically for virusinduced CPE at 4 days after virus inoculation, and the CCID5o end-point titers were calculated according to the procedure of Reed and Muench (13).
Virucidal assay. Deaza-UR was diluted in growth medium, and each drug dilution was mixed with an equal volume of a high-titered influenza virus suspension (107-CCID5o/ml) to yield a final drug concentration of 10, 32, 100, 320, or 1,000 ,g/ml. The mixtures were then incubated at 37 C for 30 min. After the exposure period, a sample of each viruscompound mixture was immediately diluted in serial 10-fold dilutions in fresh growth medium, and 1-ml amounts of each dilution were added to each of six plastic titration panel wells containing suitable MDCK cell monolayers. All panels were sealed and incubated at 37 C. Virus controls, drug cytotoxicity controls, and uninfected cell controls were handled in the same manner as the test samples. The titration panels were examined microscopically at 4 days after virus inoculation, and virus infectivity titers were determined. RESULTS Inhibition of virus-induced cytopathogenic effects in vitro. The results of the initial antiviral experiments with deaza-UR are summarized in Table 1 . It can be seen that the compound exhibited marked activity, with a VR of > 1.0 against PR8 influenza virus, coxsackievirus type A21, and rhinovirus types IA and 13. It was inactive, however, against poliovirus type 2 and echovirus type 12. It should be noted that deaza-UR was active against rhinovirus type 13 even when the challenge virus inoculum was increased from 32 to 3,200 CCID50 (Table 1) . Table 2 presents the detailed data from a single experiment concerned with the effect of deaza-UR on influenza virus-induced CPE in MDCK cells. In this particular experiment, a maximum of 75% CPE inhibition and an orderly dose response was observed with the compound. The VR of 1.3 indicated definite antiviral activity. The slight toxicity of deaza-UR for MDCK cells (7) which has been described previously (19) and which takes into account both the degree of CPE inhibition and the degree of cytotoxicity produced by the test compound. Assays were performed as described in Materials and Methods. A VR > 1.0 indicates definite antiviral activity, a VR of 0.5 to 0.9 indicates moderate or questionable antiviral activity, and a VR < 0.5 indicates inactivity.
b The concentrations of 3-deazauridine (in micrograms per milliliter) required for >50% inhibition of virus-induced CPE are given in parentheses. The challenge virus inoculum was 32 CCID50. reported in Table 2 was probably nonspecific and of unlikely significance, as no obvious cell death was observed over a 10-fold range of concentrations showing this effect. Slight toxicity was recorded only because of cytoplasmic granularity at 1,000, 320, and 100 Ag/ml.
Effect of deaza-UR on the multiplication of influenza virus. Treatment of influenza virusinfected MDCK cells with deaza-UR significantly inhibited the production of extracellular progeny virus when virus yields were examined at 12 or 24 hr after virus inoculation (Table 3) . Infected cell cultures incubated in the presence of 100 to 1,000 ,ug of deaza-UR per ml exhibited a 2-to 3-logi0 reduction in virus titer when compared with controls. Treatment of infected cells with lower concentrations of drug (10 to 32 jig of deaza-UR per ml) caused smaller reductions in virus yield (Table 3) .
Lack of direct virucidal effect of deaza-UR on influenza virus. Exposure of influenza virus to various concentrations of deaza-UR for 30 min prior to virus titration failed to inactivate the virus or cause any reduction in the titers of infectious virus present in the virus-compound incubation mixtures (Table 4) . Therefore, it is not likely that the antiviral activity observed with deaza-UR could be due to a direct virucidal action on the virus. (11, 18) . The observations reported herein on deaza-UR suggest the possibility of developing new and potentially useful drugs with broad-spectrum chemotherapeutic activity against RNA viruses. The mechanism of action of deaza-UR against these RNA viruses remains to be elucidated. Studies are now in progress to evaluate further the nucleoside analogue for antiviral activity in vitro and in vivo, and to determine (i) its effects on host cell metabolism, (ii) the degree of selectivity exhibited, and (iii) its mode of action.
DISCUSSION

